Scientists test drug combo to supercharge breast cancer treatment
NCT ID NCT03571633
Summary
This study is testing whether adding a medication called pegfilgrastim to standard pre-surgery treatment improves outcomes for people with HER2-positive breast cancer. Pegfilgrastim helps boost white blood cell counts. Researchers want to see if this boost helps the main cancer drug, trastuzumab, work better to eliminate cancer cells before surgery. The trial involves 90 participants who will receive the standard treatment with or without the additional pegfilgrastim.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU Besançon
Besançon, 25000, France
-
Centre Hospitalier Annecy Genevois
Pringy, France
-
Centre Hospitalier Universitaire de Saint Etienne
Saint-Etienne, France
-
Centre Leon Berard
Lyon, France
-
Centre de Lutte contre le Cancer Jean Perrin
Clermont-Ferrand, 63000, France
-
Clinique Charcot
Sainte-Foy-lès-Lyon, France
-
Groupe Hospitalier Mutualiste de Grenoble
Grenoble, 38000, France
-
Hopital Prive Jean Mermoz
Lyon, France
-
Institut Sainte Catherine
Avignon, France
Conditions
Explore the condition pages connected to this study.